Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Hepatology. 2016 Oct 28;64(6):1922–1933. doi: 10.1002/hep.28850

Figure 1. HC84.26.5D protects humanized mice against HCV.

Figure 1

Human liver-chimeric mice received either (A) a control HMAb, R04, or (B) HC84.26.5D at 250 mg/kg by intraperitoneal injection 24 hours prior to challenge with genotype 1b infected human serum (105 IU of HCV RNA) by intravenous injections. Viral load measurements were determined by realtime PCR at weekly intervals on an ABI model 7300 system using TaqMan chemistry (14). (C) Serum human IgG half-life measurements in mice treated with HC84.26.5D. Each timepoint was measured by ELISA in triplicates for HMAb in each mouse serum sample tested and the concentration was back-calculated based on a standard curve (S. Fig. 2).